School of Medicine
  • Print
   
   

School staff listing

People listings by divisions

 

Ian Sayers

Reader in Respiratory Molecular Genetics, Faculty of Medicine & Health Sciences

Contact

  • workLevel, D, South Block, Queen's Medical Centre
    Queen's Medical Centre
    Nottingham
    NG7 2UH
    UK
  • work0115 823 1066
  • fax0115 823 1059

Biography

Ian Sayers graduated with a B.Sc. in Biochemistry from Sheffield University, UK in 1993. He stayed at Sheffield and undertook research into the molecular basis of Immunoglobulin E (IgE) receptor interactions with a focus on therapeutic intervention in allergy graduating with a Ph.D in 1997. Dr Sayers has maintained his research interest in the molecular basis of asthma and allergy spending time with the Asthma Genetics Group in Southampton, UK (1998-2001) and in pre-clinical drug development in New Zealand at Genesis Research and Development Corporation and the Malaghan Institute (2001-2003). In 2003, Dr Sayers joined the University of Nottingham.

Expertise Summary

  • Molecular genetics
  • Primary airway cell models
  • Large scale genetic association/linkage studies
  • Recombinant protein expression in bacteria, yeast and mammalian systems
  • Site-directed mutagenesis
  • Protein purification/analysis
  • Gene expression profiling
  • Promoter-reporter technology
  • Flow cytometry
  • RNA-seq

Teaching Summary

I co-ordinate the Respiratory Medicine short course given to medical students in their 3rd year which provides a comprehensive overview of both clinical a research topics of relevance to asthma,… read more

Research Summary

Research Interests

  • Molecular and cellular mechanisms underlying Asthma & Chronic Obstructive Pulmonary Disease

I co-ordinate the Respiratory Medicine short course given to medical students in their 3rd year which provides a comprehensive overview of both clinical a research topics of relevance to asthma, COPD, lung cancer, IPF and infection.

Past Research

  • The role of IgE in asthma and allergy.
  • Pre-clinical drug development in asthma.

Future Research

Estimates suggest that 100-150 million people worldwide have asthma. In the UK the prevalence of asthma is particularly high, a recent report showed that in Scotland more than 18% of people experienced asthma symptoms and in England and Wales similar figures were reported, 17% and 15.3% respectively (Global Initiative for Asthma 2004). COPD is a composite term encompassing several diseases including chronic bronchitis and emphysema. COPD is the fourth most common cause of death worldwide (WHO 2004). Asthma and COPD are complex diseases involving both genetic and environmental factors resulting in disease expression.

Functional genomics of the IL33/ST2 axis: a therapeutic target in asthma

The interleukin 33/suppression of tumorigenicity 2 (IL33/ST2) axis has been implicated in multiple human diseases including asthma. ST2 being the receptor for IL33. In particular we and other have shown that genetic polymorphisms spanning the IL33 and IL1RL1 (gene encoding ST2) have been reproducibly associated with asthma diagnosis. ST2 can exist in multiple forms including a membrane form that signals when IL33 is bound and a soluble form thought to act as a decoy receptor. However, the causative nature of the genetic changes spanning the IL33 and IL1RL1 gene loci are unclear at this time. Interestingly, the IL33/ST2 axis may be particularly important in airway epithelial function in asthma. In a new major grant from Asthma UK we aim to further define the genetic association between variants in IL33 and ST2 genes with clinical features in asthma and importantly using tissue and primary cells from asthma patients further define the functional effects of gene polymorphism. This study brings together scientists from six centres for respiratory research across the UK, see press release.

Genetics of Asthma Severity & Phenotypes (GASP) Initiative

As part of an ongoing Asthma UK study Dr Sayers's group have developed a new cohort, the Genetics of Asthma Severity and Phenotypes (GASP) initiative that aims to generate a very large group of asthma patients with extensive clinical information for genetic studies. Recruitment is ongoing involving 16 centres across the UK. The ultimate aim is to have genome wide association data for all subjects allowing genetic association testing for asthma and clinical features of asthma. We are actively looking for new centres to collaborate.

As part of GASP we have also identified asthma patients with moderate-severe asthma and plan to conduct one of the largest severe asthma case-control analysis to date using genetic data from UK Biobank, this study is a collaboration between; University of Nottingham, University of Leicester and AirProm.

Airway remodeling genetics

We have identified the Urokinase Plasminogen Activator Receptor (UPAR/PLAUR) gene as an asthma susceptibility gene . uPAR plays a key role in the formation of the serine protease plasmin by interacting with urokinase plasminogen activator (uPA) and has been implicated in many processes including orchestrating structural changes in the airways of asthma patients called airway remodeling. Airway remodeling is characterized by; smooth muscle hypertrophy/hyperplasia, sub-epithelial fibrosis, basement membrane thickening, increased extracellular matrix (ECM) deposition and more recently epithelial metaplasia and goblet cell hyperplasia have been identified. Airway remodeling leads to accelerated decline in lung function in asthma, and is not adequately targeted by existing asthma drugs. We have identified that uPAR is elevated in the bronchial epithelium in asthma and contributes to wound/repair responses providing evidence for a role in airway structural changes.Ongoing studies aim to determine the mechanistic basis of this association and explore the potential of targeting uPAR in asthma for clinical benefit.

Lung function genetics

Forced Expiratory Volume in 1 second (FEV1) and FEV1/Forced Vital capacity (FVC) ratio are important predictors of population morbidity and mortality and form the basis of the diagnosis of COPD. Hereditability estimates for FEV1 are as high as 0.77. Using Genome Wide Association (GWA) approaches in 20,288 individuals of European decent (Phase 1) and ≥32,184 additional individuals (Phase 2) we identified association with common variants in TNS1, GSTCD and HTR4 for FEV1 and HHIP, AGER and THSD4 for FEV1/FVC (see manuscript). Ongoing studies aim to determine the functional significance of these associated polymorphism and their contribution to COPD.

Targeting the airway epithelium in asthma

The airway epithelium represents a critical interface between the environment and the tissue of the airways. Under normal conditions the epithelium is composed of ciliated columnar, mucus secreting goblet and Clara cells that secrete surfactant. In asthma, epithelial desquamation and dysfunction including impaired barrier function and repair capacity have been reported. Epithelial damage and abnormal repair shows a correlation with the development of bronchial hyper-responsiveness (BHR) in asthma subjects. Ongoing studies aim to further our understanding of molecular mechanisms underlying these alterations in airway epithelial function using ex vivo models and may provide therapeutic opportunities for asthma. Similarly, we are developing new sampling techniques to obtain primary airway epithelial cells from the airways of asthma and control subjects to further study disease specific mechanisms (in collaboration with Dr Dominick Shaw).

Collaborators

Prof. Ian Hall, Dr. Dominick Shaw, Dr Cynthia Bosquillon (Nottingham)

Prof. Christopher Brightling (Leicester), Prof. John Holloway (Southampton), Prof. Gerard Koppelman (Groningen), Dr. Bianca Beghé (Modena), Prof. Angela Simpson (Manchester), Dr. Adel Mansur (Birmingham), Prof. Neil Thomson (Glasgow), Dr. Charlotte Dean (Imperial)

Research Fellows

Michael Portelli

Current PhD Students

Sangita Bhatti, Abdul Kheirallah, Kelly Probert, Jon Lewis, Amanda Lewis, Robert Hall, Binaya KC

Previous PhD Students

Catherine Gowland (Awarded 2015), Mariel Slater (Awarded 2014) Michael Portelli (Awarded 2013) Ma'en Obeidat (Awarded 2012) Jane Fox (Awarded 2011) Yize Wan (Awarded 2011) Emily Hodge (Awarded 2011) Asif Tulah (Awarded 2010) Khalid Al Balushi (Awarded 2009) Samantha Peel (Awarded 2008)

Funding

Asthma UK

British Lung Foundation

Nottingham Hospitals Charity British Medical Association MRC University of Nottingham Pfizer

School of Medicine

University of Nottingham
Medical School
Nottingham, NG7 2UH

Contacts: Please see our 'contact us' page for further details